Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.43 |
| ▸ | NOS3 | P29474 | 2/20 | 0.43 |
| ▸ | NOS2 | P35228 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | NOS1 | P29475 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15232687 | 0.86 | DYRK1A (0.53) | DYRK1AKMT2AMAPTCLK4KDR | |
| SCHEMBL1165314 | 0.84 | FYN (0.52) | DYRK1AMAPTCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4938505 | 0.80 | DYRK1A (0.54) | DYRK1AKMT2AMAPTCLK4MAP4K4 | |
| SCHEMBL13730604 | 0.79 | NOS3 (0.52) | KMT2AMAPTKDRMAP4K4MEN1 | |
| SCHEMBL20522368 | 0.79 | CLK4 (0.56) | DYRK1AKMT2AMAPTCLK4KDR | |
| SCHEMBL17555617 | 0.78 | FYN (0.44) | DYRK1AKMT2AMAPTMEN1KDM4E | |
| SCHEMBL28083154 | 0.77 | CLK4 (0.53) | DYRK1AKMT2AMAPTCLK4MEN1 | |
| SCHEMBL4930996 | 0.77 | DYRK1A (0.44) | DYRK1AKMT2AMAPTCLK4KDR | |
| SCHEMBL5319523 | 0.76 | NOS2 (0.44) | KDRNOS3NOS2NPC1RAB9A | |
| SCHEMBL29092217 | 0.76 | HSP90AA1 (0.50) | DYRK1ANOS3NOS2NPC1NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255085-A1 | Novel Imidazo [4,5-b] Pyridine Derivatives as Inhibitors of Glycogen Synthase Kinase 3 for Use in the Treatment of Dementia and Neurodegenerative Disorders | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | US | claimed |
| EP-1937680-A2 | NOVEL IMIDAZO [4,5 -B] PYRIDINE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 FOR USE IN THE TREATMENT OF DEMENTIA AND NEURODEGENERATIVE DISORDERS | AstraZeneca AB (SE) | 2008-07-02 | — | — | EP | claimed |
| WO-2007040438-A2 | NOVEL IMIDAZO [4,5 -B] PYRIDINE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 FOR USE IN THE TREATMENT OF DEMENTIA AND NEURODEGENERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | WO | claimed |
| WO-2023050168-A1 | RETARDANT COMPOSITION AND DYE KIT COMPRISING THEREOF | L'OREAL (FR) | 2023-04-06 | — | — | WO | disclosed |
| WO-2023272588-A1 | RETARDANT COMPOSITION OF OXIDATION | L'OREAL (FR) | 2023-01-05 | — | — | WO | disclosed |
| WO-2023272863-A1 | COMBINATION FOR DYEING KERATIN FIBERS AND USE THEREOF | L'OREAL (FR) | 2023-01-05 | — | — | WO | disclosed |
| WO-2023272610-A1 | DYE KIT | L'OREAL (FR) | 2023-01-05 | — | — | WO | disclosed |
| EP-3989925-A1 | COMPOSITION FOR DYEING KERATIN FIBERS AND USE THEREOF | L'Oreal (FR) | 2022-05-04 | — | — | EP | disclosed |
| EP-3990120-A1 | COMPOSITION FOR DYEING KERATIN FIBRES AND USE THEREOF | L'OREAL (FR) | 2022-05-04 | — | — | EP | disclosed |
| EP-3989924-A1 | COSMETIC COMPOSITION FOR THE OXIDATIVE DYEING OF KERATIN FIBRES | L'Oreal (FR) | 2022-05-04 | — | — | EP | disclosed |
| WO-2020259215-A1 | COMPOSITION FOR DYEING KERATIN FIBRES AND USE THEREOF | L'OREAL (FR) | 2020-12-30 | — | — | WO | disclosed |
| EP-2315573-A2 | METHODS AND KITS FOR PERMANENTLY COLORING HAIR USING A DEVELOPER COMPOSITION CONTAINING AN OXIDIZER COMPOSITION AND A SHAMPOO | L'Oréal (FR) | 2011-05-04 | — | — | EP | disclosed |
| WO-2010023559-A2 | METHODS AND KITS FOR PERMANENTLY COLORING HAIR USING A DEVELOPER COMPOSITION CONTAINING AN OXIDIZER COMPOSITION AND A SHAMPOO | L'OREAL (FR) | 2010-03-04 | — | — | WO | disclosed |
| US-20080255085-A1 | Novel Imidazo [4,5-b] Pyridine Derivatives as Inhibitors of Glycogen Synthase Kinase 3 for Use in the Treatment of Dementia and Neurodegenerative Disorders | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | US | disclosed |
| US-20080255085-A1 | Novel Imidazo [4,5-b] Pyridine Derivatives as Inhibitors of Glycogen Synthase Kinase 3 for Use in the Treatment of Dementia and Neurodegenerative Disorders | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | US | disclosed |
| US-20080255085-A1 | Novel Imidazo [4,5-b] Pyridine Derivatives as Inhibitors of Glycogen Synthase Kinase 3 for Use in the Treatment of Dementia and Neurodegenerative Disorders | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | US | disclosed |
| EP-1937680-A2 | NOVEL IMIDAZO [4,5 -B] PYRIDINE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 FOR USE IN THE TREATMENT OF DEMENTIA AND NEURODEGENERATIVE DISORDERS | AstraZeneca AB (SE) | 2008-07-02 | — | — | EP | disclosed |
| US-20080021069-A1 | Receptor Function Regulating Agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-24 | — | — | US | disclosed |
| EP-1810677-A1 | RECEPTOR FUNCTION REGULATING AGENT | Takeda Pharmaceutical Company Limited (JP) | 2007-07-25 | — | — | EP | disclosed |
| WO-2007040438-A2 | NOVEL IMIDAZO [4,5 -B] PYRIDINE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 FOR USE IN THE TREATMENT OF DEMENTIA AND NEURODEGENERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255085-A1 | Novel Imidazo [4,5-b] Pyridine Derivatives as Inhibitors of Glycogen Synthase Kinase 3 for Use in the Treatment of Dementia and Neurodegenerative Disorders | GSK3B, GSK3A, PYGB | DYRK1A 45/4885KMT2A 2034/4885MAPT 30/4885 |
| US-20080021069-A1 | Receptor Function Regulating Agent | GPR119, INSR, GPR65 | DYRK1A 2423/4885KMT2A 1963/4885MAPT 4574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.